TY - JOUR
T1 - Overcoming psychological insulin resistance
T2 - A practical guide for healthcare professionals
AU - Snoek, Frank J.
AU - Fisher, Lawrence
AU - Polonsky, William H.
AU - Stuckey, Heather
AU - Hessler, Danielle
AU - Tang, Tricia
AU - Hermanns, Norbert
AU - Mundet, Xavier
AU - Silva, Maria
AU - Sturt, Jackie
AU - Okazaki, Kentaro
AU - Hadjiyianni, Irene
AU - Desai, Urvi
AU - Perez-Nieves, Magaly
N1 - Funding Information: FJS has served as consultant for Eli Lilly, Sanofi and Roche, and has received research funding from Sanofi. WHP has served as a consultant for Eli Lilly, Novo Nordisk, and Sanofi. JS has served as a consultant for Eli Lilly, Novo Nordisk, and Spirit Healthcare. NH reports grants and personal fees from Abbott Diabetes Care,Berlin Chemie,Astrazeneca,Lilly,Dexcom, andRoche. KO has served as a consultant for Eli Lilly Japan K.K., SANWA KAGAKU KENKYUSHO CO., LTD., Kowa Company, Limited, ARKRAY, Inc., Sanofi K.K., Mitsubishi Tanabe Pharma Corporation, Abbott Japan LLC, Novo Nordisk Pharma Ltd., MSD K.K., Astellas Pharma Inc., TERUMO CORPORATION, and ONO PHARMACEUTICAL CO., LTD. LF, MS, XM, DH, and HS have served as consultants for Eli Lilly. MPN is an employee of Eli Lilly and Company. UD is an employee of Analysis Group, Inc., a company that received funding for this research from Eli Lilly and Company. IH was an employee of Lilly Deutschland GmbH at the time of the study. Funding Information: FJS has served as consultant for Eli Lilly, Sanofi and Roche, and has received research funding from Sanofi. WHP has served as a consultant for Eli Lilly, Novo Nordisk, and Sanofi. JS has served as a consultant for Eli Lilly, Novo Nordisk, and Spirit Healthcare. NH reports grants and personal fees from Abbott Diabetes Care, Berlin Chemie, Astrazeneca, Lilly, Dexcom, and Roche. KO has served as a consultant for Eli Lilly Japan K.K., SANWA KAGAKU KENKYUSHO CO., LTD., Kowa Company, Limited, ARKRAY, Inc., Sanofi K.K., Mitsubishi Tanabe Pharma Corporation, Abbott Japan LLC, Novo Nordisk Pharma Ltd., MSD K.K., Astellas Pharma Inc., TERUMO CORPORATION, and ONO PHARMACEUTICAL CO., LTD. LF, MS, XM, DH, and HS have served as consultants for Eli Lilly. MPN is an employee of Eli Lilly and Company. UD is an employee of Analysis Group, Inc., a company that received funding for this research from Eli Lilly and Company. IH was an employee of Lilly Deutschland GmbH at the time of the study. Publisher Copyright: © 2021 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Despite the demonstrated benefits of using insulin, nearly a third of the patients with type 2 diabetes (T2D) are initially reluctant to initiate insulin therapy when it is first recommended by their healthcare provider (HCP). Several studies have documented the reasons for this phenomenon known as psychological insulin resistance (PIR) and also identified actionable strategies for HCPs to assist people with T2D to overcome their PIR. However, most strategies are based on the experiences of HCPs, rather than of patients. Based on findings from a study exploring real-world patient experience around HCP actions for mitigating PIR, we suggest that HCPs use collaborative strategies throughout the course of T2D treatment to 1) explore reasons for PIR, 2) help patients overcome PIR, and 3) follow-up regarding experience with insulin.
AB - Despite the demonstrated benefits of using insulin, nearly a third of the patients with type 2 diabetes (T2D) are initially reluctant to initiate insulin therapy when it is first recommended by their healthcare provider (HCP). Several studies have documented the reasons for this phenomenon known as psychological insulin resistance (PIR) and also identified actionable strategies for HCPs to assist people with T2D to overcome their PIR. However, most strategies are based on the experiences of HCPs, rather than of patients. Based on findings from a study exploring real-world patient experience around HCP actions for mitigating PIR, we suggest that HCPs use collaborative strategies throughout the course of T2D treatment to 1) explore reasons for PIR, 2) help patients overcome PIR, and 3) follow-up regarding experience with insulin.
KW - Patient-provider relationship
KW - Psychological insulin resistance
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85103411352&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/33785288
UR - http://www.scopus.com/inward/record.url?scp=85103411352&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.pcd.2021.03.001
DO - https://doi.org/10.1016/j.pcd.2021.03.001
M3 - Comment/Letter to the editor
C2 - 33785288
SN - 1751-9918
VL - 15
SP - 619
EP - 621
JO - Primary care diabetes
JF - Primary care diabetes
IS - 3
ER -